Actuate Therapeutics, Inc. Common stock (ACTU) Análisis de acciones

Descripción de la empresa

Actuate Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of therapeutic interventions for cancer treatment within the United States market. The company functions within the healthcare sector, specifically targeting the biotechnology industry, which implies a focus on innovative drug discovery and clinical trial execution rather than established product sales. In terms of scale, Actuate Therapeutics reports a market capitalization of $50.27M and employs a workforce of 12 individuals, reflecting the typical size profile of a pre-revenue biotech venture. The absence of reported annual revenue alongside a market cap of $50.27M indicates that the company's valuation is derived primarily from its pipeline assets and potential future commercialization prospects rather than current cash generation or market share.

Salud financiera

The company reports a net income of $-22,227,852 over the trailing twelve-month period, while both revenue and EBITDA are listed as N/A, revealing a cost structure where expenses significantly exceed any current income streams. This negative net income relative to the lack of revenue highlights the substantial capital burn rate inherent in the clinical-stage development phase before product launch. The free cash flow stands at $-11,038,870, indicating that the company is consuming cash reserves to fund operations and research activities rather than generating liquidity. Regarding profitability metrics, the gross margin is 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, which collectively signify that the company has not yet achieved commercial sales necessary to generate traditional profit margins. The balance sheet holds $13.16M in cash against N/A debt, suggesting a conservative leverage position where the company relies on equity financing rather than borrowed capital to sustain its burn rate. Although debt figures are unavailable, the current ratio of 2.39 demonstrates a strong short-term liquidity position, implying that the company possesses sufficient current assets to cover its current liabilities more than twice over. Furthermore, the return on equity is -553.7% and the return on assets is -120.4%, metrics that reflect the aggressive investment phase where losses are being incurred against the equity and asset base to advance clinical trials.

Evaluación de valoración

The P/E ratio (TTM) is N/A due to the lack of earnings, while the forward P/E is reported as -2.10, a figure that typically signals negative earnings expectations or a market pricing model that accounts for anticipated losses in the coming period. The price-to-book ratio is 6.22, indicating that the market values the company at more than six times its net asset value, which suggests a high premium assigned to its intellectual property and pipeline potential despite current financial deficits. Since revenue is N/A, the price-to-sales ratio and EV/EBITDA are also N/A, meaning these alternative valuation metrics are not currently applicable for assessing the company's revenue efficiency or earnings multiple. The stock's 52-week trading range spans from a low of $1.81 to a high of $11.99, placing the current valuation context within a wide band of volatility typical for small-cap biotechnology firms. The beta value is N/A, which precludes a direct comparison of the stock's volatility against the broader market index using this specific metric.

Growth & Income

Revenue growth and earnings growth rates are both listed as N/A, as the company has not yet generated positive revenue streams to calculate year-over-year growth percentages. Consequently, the company does not distribute dividends, resulting in a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available financial resources are being reinvested into research and development rather than shareholder distributions. The lack of a dividend yield aligns with the strategic imperative for clinical-stage companies to prioritize capital allocation toward advancing their lead product candidates through regulatory approval processes. The overall growth and income profile is characterized by a reliance on future commercialization events to transform current losses into revenue, rather than providing current income or historical growth data for analysis.